AI News · Hot news ·
OpenAI acquires Orchestra Bio to add biotech agents to its Rosalind tools
OpenAI acquired Orchestra Bio, a four-year-old startup that builds AI agents for biotech operations such as finance tracking and clinical trial scheduling. The team and technology will be folded into Rosalind, OpenAI's life sciences model, and Rosalind Workbench. Terms were not disclosed.
Key points
- OpenAI bought Orchestra Bio, which builds AI agents for biotech operations.
- The team and technology join Rosalind and Rosalind Workbench, OpenAI's life sciences tools.
- OpenAI did not disclose the price; Orchestra reportedly raised about $20 million.
What happened: OpenAI acquired Orchestra Bio on Tuesday, announcing the deal on its website, TechCrunch reported. Orchestra is a four-year-old startup that builds AI agents to handle operational work for biotech companies. The purchase price and deal terms have not been disclosed.
The details: Orchestra's agents handle tasks such as tracking finances and resolving clinical trial scheduling conflicts. OpenAI is folding the team and technology into Rosalind, its AI model for life sciences research, and Rosalind Workbench, a tool meant to help researchers plan experiments and analyze results. OpenAI says Moderna and Novo Nordisk are Rosalind customers. Orchestra reportedly raised around $20 million as of 2025 from backers including Andreessen Horowitz, Atria and 8VC.
Background: TechCrunch described the deal as an example of the largest AI labs, including OpenAI and Anthropic, building more software for major industries such as pharma. Startups often fear that labs will launch competing features. In this case, the report noted, Orchestra is being absorbed rather than pushed out.
What to watch: OpenAI has not said whether Orchestra's standalone product will continue or how many employees are joining. The number of founders and the headcount were not reported. Biotech customers of Orchestra will want clarity on how the product is supported once it is combined with Rosalind.
Our take
AI labs are building industry-specific agent software themselves, so teams buying vertical AI tools should weigh how labs may absorb or compete with those vendors.